Cardiovascular Systems, Inc. (CSII) Sets 52-Week High on Jun, 27

June 27, 2018 - By Robert Case

During Q1 2018 the big money sentiment decreased to 0.86. That’s change of 0.16, from 2017Q4’s 1.02. 17 investors sold all, 42 reduced holdings as Cardiovascular Systems, Inc. ratio fall. 34 grew positions while 17 funds acquired positions. Funds hold 26.24 million shares thus 0.31% more from 2017Q4’s 26.16 million shares.
Swiss Bank reported 0% of its capital in Cardiovascular Systems, Inc. (NASDAQ:CSII). Stratos Wealth Prtnrs has invested 0.01% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Aqr Mngmt Lc has invested 0% of its capital in Cardiovascular Systems, Inc. (NASDAQ:CSII). Moreover, Wells Fargo & Mn has 0% invested in Cardiovascular Systems, Inc. (NASDAQ:CSII). First Light Asset Mgmt Ltd Company owns 469,687 shs or 2.26% of their US capital. First Mercantile Trust Company has invested 0.06% of its capital in Cardiovascular Systems, Inc. (NASDAQ:CSII). Barclays Public Limited reported 0% stake. Bluecrest Cap Mngmt Ltd owns 13,150 shs or 0.01% of their US capital. Amer Int Group Inc Incorporated invested 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII). California State Teachers Retirement Sys has 0% invested in Cardiovascular Systems, Inc. (NASDAQ:CSII). Numerixs Inv Tech stated it has 4,700 shs or 0.03% of all its holdings. State Street, a Massachusetts-based fund reported 761,214 shs. Citigroup reported 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Zurcher Kantonalbank (Zurich Cantonalbank) invested 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII). The Massachusetts-based Fmr Limited Company has invested 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII).

A one-year high was broke into by Cardiovascular Systems, Inc. (NASDAQ:CSII). Today’s stock price was $33.68. It’s 4.00 % above our $35.02. On Jun, 27 it was announced by The company has $1.12 billion MC. $44.80 million more could be NASDAQ:CSII valuation at $35.02 share price.

Ticker’s shares touched $33.675 during the last trading session after 9.41% change.Cardiovascular Systems, Inc. is uptrending after having risen 0.43% since June 27, 2017. CSII has 295,464 volume or 38.30% up from normal. CSII underperformed by 12.14% the S&P500.

Earnings report for Cardiovascular Systems, Inc. (NASDAQ:CSII) is anticipated on August, 1., according to Zacks. Analysts forecast $0.06 EPS, which is $0.04 up or 200.00 % from 2017’s $0.02 EPS. The profit will be $2.00 million for CSII if $0.06 EPS becomes true. Wall Street sees 500.00 % EPS growth as of August, 1.

More recent Cardiovascular Systems, Inc. (NASDAQ:CSII) news were brought out by, and The first one has “Cardiovascular Systems gets two-notch upgrade at BAML” as a title and was brought out on June 27, 2018. The next is “BofA/Merrill Lynch Double Upgrades Cardiovascular Systems (CSII) to Buy” on June 27, 2018. And last was brought out on June 19, 2018, called “Detailed Research: Economic Perspectives on LSC Communications, Cardiovascular, RPX, Nustar Energy, LSB …”.

Cardiovascular Systems, Inc., a medical technology company, develops, makes, and markets devices to treat vascular diseases in the United States.The firm is valued at $1.12 billion. The firm offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System , Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.Currently it has negative earnings. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries.

Cardiovascular Systems, Inc. (NASDAQ:CSII) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.